[Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 21,413.4 Million by 2033 at a 5.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
December 10, 2024 11:30 ET
|
Custom Market Insights
Austin, TX, USA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Gastrointestinal Endoscopy Devices Market Size, Trends and Insights By Product...
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
July 24, 2024 14:00 ET
|
Spherix Global Insights
EXTON, PA, July 24, 2024 (GLOBE NEWSWIRE) -- Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to autoantibodies. Among...
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
July 24, 2024 09:56 ET
|
Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 (GLOBE NEWSWIRE) -- The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking...
[Latest] US Diabetes Devices Market Size/Share Worth USD 19.8 Billion by 2033 at a 7.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 23, 2024 13:30 ET
|
Custom Market Insights
Austin, TX, USA, July 23, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Diabetes Devices Market Size, Trends and Insights By Type (Blood Glucose...
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
May 28, 2024 07:35 ET
|
Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
November 30, 2023 10:59 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
Global WholeHealth Partners Corp (OTC: GWHP) to Announce that Global is Now Offering All 4 Major Vaccines (AstraZeneca, J&J, Pfizer, Moderna) as Mentioned in 8k Filings 03/08/21, 06/09/21, 06/15/21, and 06/24/21
August 09, 2021 07:00 ET
|
Global WholeHealth Partners Corp.
The Vaccines Have Been Verified to Assist in the Protection Against the Delta Variant SAN CLEMENTE, CA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global WholeHealth Partners Corp...
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
June 10, 2021 07:20 ET
|
Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
March 29, 2021 08:30 ET
|
Dyadic International, Inc.
Advancing Dyadic’s proprietary owned COVID-19 vaccine candidate, DYAI-100, towards first-in-human Phase 1 clinical trial Engaged CR2O, a contract research organization, to manage and support further...
RenovaCare to Present at BioNJ/JP Morgan/J&J BioPartnering Conference
September 15, 2020 08:30 ET
|
RenovaCare, Inc.
ROSELAND, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the...